The study of efficacy of lamivudine in patients with severe acute hepatitis B

Digestive Diseases and Sciences

Volumn 55, Issue 3, 2010, Pages 775-783

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Zhao, Yong Hua ^a   Kang, Peng ^a   Li, Shu Chen ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute; Hepatitis B; Lamivudine; Severe

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BILIRUBIN; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; HEPATITIS B; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SURVIVAL RATE; VIRUS LOAD; ACUTE DISEASE; BLOOD; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ACUTE DISEASE; ADULT; AGED; ANTI-HIV AGENTS; BILIRUBIN; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 77949332709     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1060-5     Document Type: Article

References (19)

1. G Ostapowicz RJ Fontana FV Schiodt, et al. 2002 U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann Intern Med 137 947 954 12484709
2. RN Chien CH Lin YF Liaw 2003 The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B J Hepatol 38 322 327 10.1016/S0168-8278(02)00419-1 1:CAS:528:DC%2BD3sXhtVemtbk%3D 12586298 (Pubitemid 36286545)
3. JH Hoofnagle E Doo TJ Liang R Fleischer AS Lok 2007 Management of hepatitis B: Summary of a clinical research workshop Hepatology 45 1056 1075 10.1002/hep.21627 1:CAS:528:DC%2BD2sXltlWitb0%3D 17393513 (Pubitemid 46646501)
4. R Reshef W Sbait R Tur-Kaspa 2000 Lamivudine in the treatment of acute hepatitis B N Engl J Med 343 1123 1124 10.1056/NEJM200010123431513 1:STN:280:DC%2BD3cvotl2mtA%3D%3D 11032526
5. N Torii K Hasegawa M Ogawa, et al. 2002 Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B Hepatol Res 24 34 41 10.1016/S1386-6346(02)00009-8 1:CAS:528:DC%2BD38XntVajsbY%3D 12243790
6. L Roznovsky I Orságová A Kloudová, et al. 2007 Lamivudine therapy in patients with severe acute hepatitis B Klin Mikrobiol Infekc Lek 13 59 65 1:STN:280:DC%2BD2svgs1eltg%3D%3D 17599294 (Pubitemid 47201658)
7. HL Tillmann J Hadem L Leifeld, et al. 2006 Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience J Viral Hepat 13 256 263 10.1111/j.1365-2893.2005.00695.x 1:STN:280:DC%2BD283gsFOqsQ%3D%3D 16611192
8. A Lisotti F Azzaroli F Buonfiglioli, et al. 2008 Lamivudine treatment for severe acute HBV hepatitis Int J Med Sci 5 309 312 1:CAS:528:DC%2BD1cXhsFSns7bI 18974858
9. M Kumar S Satapathy R Monga, et al. 2007 A randomized controlled trial of lamivudine to treat acute hepatitis B Hepatology 45 97 101 10.1002/hep.21486 1:CAS:528:DC%2BD2sXht1arsbg%3D 17187417 (Pubitemid 46144369)
10. S Sainokami K Abe A Sato, et al. 2007 Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection J Gastroenterol 42 241 249 10.1007/s00535-006-1997-5 1:CAS:528:DC%2BD2sXjtlygsL8%3D 17380283 (Pubitemid 46488234)
11. JG O'Grady GJ Alexander KM Hayllar R Williams 1989 Early indicators of prognosis in fulminant hepatic failure Gastroenterology 97 439 455 2490426 (Pubitemid 19192181)
12. Liver Failure and Artificial Liver Group Chinese Society of Infectious Diseases Chinese Medical Association and Severe Liver Diseases and Artificial Liver Group Chinese Society of Hepatology Chinese Medical Association 2006 Diagnostic and treatment guidelines for liver failure Zhonghua Gan Zang Bing Za Zhi 14 643 646
13. M Sterneck S Gunther T Santantonio L Fisher C Broelsch H Greten, et al. 1996 Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation Hepatology 24 300 306 10.1002/hep.510240203 1:CAS:528:DyaK2sXisFejt7s%3D 8690396 (Pubitemid 26260023)
14. H Schmilovitz-Weiss Z Ben-Ari E Sikuler, et al. 2004 Lamivudine treatment for acute severe hepatitis B: A pilot study Liver Int 24 547 551 10.1111/j.1478-3231.2004.0983.x 1:CAS:528:DC%2BD2MXmtVaitQ%3D%3D 15566503 (Pubitemid 40028605)
15. RK Dhiman AK Seth S Jain YK Chawla JB Dilawari 1998 Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis Dig Dis Sci 43 1311 1316 10.1023/A:1018876328561 1:STN:280:DyaK1c3pslGntQ%3D%3D 9635624 (Pubitemid 28272568)
16. Y Miyake Y Iwasaki A Takaki, et al. 2008 Lamivudine treatment improves the prognosis of fulminant hepatitis B Inter Med 47 1293 1299 10.2169/internalmedicine.47.1061
17. JW Yu GQ Wang YH Zhao LJ Sun SQ Wang SC Li 2007 The MELD scoring system for predicting prognosis in patients with severe hepatitis after plasma exchange treatment Hepatobiliary Pancreat Dis Int 6 492 496 17897912 (Pubitemid 47521163)
18. JW Yu LJ Sun YH Zhao, et al. 2008 Prediction value of MELD scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment J Gastroenterol Hepatol 23 1242 1249 10.1111/j.1440-1746.2008.05484.x 1:CAS:528:DC%2BD1cXhtFensbnI 18637053
19. WO Bocher S Herzog-Hauff W Herr, et al. 1996 Regulation the neutralizing anti-hepatitis B surface (HBS) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection Clin Exp Immunol 105 52 58 10.1046/j.1365-2249.1996.d01-732.x 1:STN:280:DyaK283otVOktQ%3D%3D 8697635 (Pubitemid 26231823)